Valsamo Anagnostou, Co-Director of Thoracic Oncology Precision Medicine Center of Excellence and Division of Upper Aerodigestive Malignancies and Alex Grass Professor of Oncology at Johns Hopkins University School of Medicine, shared a post on LinkedIn:
“Nature Portfolio npj | Precision Oncology has just launched a special collection on Minimal Residual Disease and Circulating Tumor DNA Dynamics in Personalized Cancer Treatment, and I am pleased to serve as the Series Editor.
The goal of this Collection is to showcase cutting-edge liquid biopsy research spanning a broad range of topics, from liquid biopsy technology and cell-free DNA biology to clinical applications, and to highlight the emerging role of ctDNA residual disease in therapy optimization, thereby epitomizing precision cancer intervention and therapy.
We welcome original research articles, comprehensive reviews, clinical case reports, and perspective pieces exploring!
The submission deadline is March 12, 2027; please don’t hesitate to reach out if you would like to discuss!
Excited for a remarkable collection that will advance the field of liquid biopsies!”
Other articles featuring Valsamo Anagnostouon OncoDaily.